For biopharma
Biopharma commercial teams need biomarker testing data, not a modeled estimate of it. Hyperdrive aggregates it directly from pathology and genomics reference labs, shows which providers are testing, alerts you when a result creates an eligible patient, and surfaces the places in the community where testing is not happening at all.
Explore commercial analytics60K
HER2 IHC across tumors, a year
20K
ER/PR in breast, a year
30K
Heme and solid tumor liquid biopsies, a year
20K
Comprehensive genomic solid tumor profiles, a year
A targeted therapy only reaches a patient whose biomarker was tested for and confirmed. By the time that appears in claims data, the treatment decision has usually been made, and the field team learns about the account a quarter after it mattered.
The harder problem is absence. A provider who never orders the test generates no signal at all, so the patients who would have been eligible are invisible in the data your team works from.
01
Segment the market by the markers your brand depends on — ER, PR, HER2, PD-L1 and genomic markers, across single-analyte testing and next-generation sequencing. Work from a list built around your therapy rather than a specialty code.
02
A first order, a confirmed result, a shift in a testing pattern. Hyperdrive flags it against a specific biomarker or ICD-10 code the same day, so the field reaches the provider while the decision is still open.
03
The same view surfaces where testing is not happening. Identify the community providers who are not ordering, so gaps can be closed and precision medicine reaches the patients whose care depends on it. See testing gaps.
Biomarker testing data shows eligibility at the moment a test result is confirmed. Claims data reports the same event weeks or months later, usually after the treatment decision. Hyperdrive works from laboratory results, so field teams reach the provider while the decision is still open.
Hyperdrive segments the market by ER, PR, HER2, PD-L1 and genomic markers across single-analyte testing and next-generation sequencing. The network sees about 60,000 HER2 IHC tests, 30,000 liquid biopsies and 20,000 comprehensive genomic profiles a year.
Same day. Hyperdrive flags a first order, a confirmed result or a change in a provider's testing pattern against the specific biomarker or ICD-10 code your brand is built around, so the field team can act before the treatment decision is made.
Yes. Hyperdrive surfaces community providers who are not ordering the tests your therapy depends on. Those testing gaps are where eligible patients are invisible in claims data, and where closing the gap brings precision medicine to more patients.
No. Data is de-identified under HIPAA Safe Harbor or Expert Determination inside Hyperdrive's Nexus platform and summarized to the individual healthcare provider. No protected health information is shared with biopharma.
Tell us the brand, the biomarker and the geography. We will show you the providers, cohorts and triggers Hyperdrive would hand your field team, on data you can check. The target list we build on the call is yours to keep.